Desk›Healthcare› Transgene Biotek Ltd
Transgene Biotek Ltd
BSE 526139 · NSE TRABI · ISIN INE773D01018 · Group X · Active
Healthcare › Healthcare › Healthcare Services › Healthcare Service Provider
₹2.88
+2.13%
BSE close, 28 August 2026
₹18.94 cr
6.6 cr shares · Micro cap
₹14.83 cr
as published
-13.7× · -3.24×
EPS ₹-0.21 · BV ₹-0.89
0.21 / -1.65
₹ cr, as filed
12
3 selected · 25%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -36.0% |
|---|---|
| Against 52-week low | +57.4% |
| Day change | +2.13% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹-0.21 |
|---|---|
| Price / earnings | -13.71× |
| Price / book | -3.24× |
| Book value — derived, price ÷ P/B | ₹-0.89 |
| Return on equity | 23.84% |
| Operating margin | -96.67% |
| Net margin | -648.33% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 23.63%
- ROE as published
- 23.84%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 0.06 | -0.39 | -0.05 | -96.67% | -648.33% |
| Mar-26 · Q | 0.06 | -0.46 | -0.06 | -236.36% | -830.91% |
| FY25-26 | 0.21 | -1.65 | -0.22 | -186.73% | -783.41% |
Quarter on quarter
- Revenue, quarter on quarter
- +0.0%
- Net profit, quarter on quarter
- +15.2%
- Operating margin, quarter on quarter
- +13,969 bps
Disclosure profile 12 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Auditor Resignation | 1 |
| Board Outcome | 1 |
| Results | 1 |
| Selected sub-total | 3 |
| Procedural | |
| Other Update | 3 |
| Board Meeting | 2 |
| Trading Window | 2 |
| General | 1 |
| Newspaper Publication | 1 |
| Procedural sub-total | 9 |
| Total | 12 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group X, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
12 filings · 3 selected · busiest 2026-07-22
Filing rhythm · the twelve most recent
2026-07-222026-10-02
SelectedProcedural
Filings
12 in the window · 1 earlier on record
-
2 October 2026 ·
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Transgene Biotek Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/10/2026 ,inter alia, to consider and approve To consider and approve the ....
Board Meeting / Board Meeting View filing →
-
25 September 2026 ·
Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, We Wish To Inform You That The Company Has Received Approval From The Registrar Of Companies (ROC), Hyderabad, Telangana, For Extension Of Time For Holding The 36Th Annual General Meeting (AGM) Of The Company For The Financial Year Ended March 31, 2026.
Intimation Extension of time for holding 36th Annual General Meeting of the Company for the Financial year ended on March 31, 2026.
Company Update / General View filing →
-
23 September 2026 ·
Resignation of Statutory Auditors
Intimation of Resignation of Statutory Auditors-M/s. Vasavi & Co., Chartered Accountants (FRN:020965S).
Company Update / Resignation of Statutory Auditors View filing →
-
22 September 2026 ·
Closure of Trading Window
Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
22 September 2026 ·
Closure of Trading Window
Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
11 August 2026 ·
-
7 August 2026 ·
526139 - 1)The Board Considered And Approved The Unaudited Financial Results (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2026. 2) The Board Considered And Approved The Limited Review Report (Standalone & Consolidated) Of The Company For The Quarter Ended 30Th June 2026.
Unaudited Financial Results for the quarter ended 30th June 2026.
Result / Financial Results View filing →
-
7 August 2026 ·
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On August 07, 2026.
Sub: Outcome of the Meeting of the Board of Directors held on August 07, 2026. This has reference to our letter dated 22nd July 2026, Intimating the meeting of the Board of Directors of ....
Board Meeting / Outcome of Board Meeting View filing →
-
23 July 2026 ·
Board Meeting Intimation for Intimation Of The Board Meeting.
Transgene Biotek Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
Board Meeting / Board Meeting View filing →
-
22 July 2026 ·
Compliance-57 (4) : Prior intimation to the beginning of the quarter
Compliance - 57(4)
Others / 57 (4) : Prior intimation to the beginning of the quarter View filing →
-
22 July 2026 ·
Statement Of Deviation & Variation
Statement of Deviation & Variation
Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation View filing →
-
22 July 2026 ·
Compliance-57 (5) : intimation after the end of quarter
Compliance -57 (5)
Others / 57 (5) : intimation after the end of quarter View filing →
RSS feed for Transgene Biotek Ltd · the 50 most recent filings